Search results
Results from the WOW.Com Content Network
In 1979 a new edition was published with a new title, The Pharmaceutical Codex. The Medicines Commission had recommended in 1972 that the British Pharmacopoeia should henceforth be the only compendium of official standards for medicines in the UK, and the BPC lost its status as an official book. The PSGB remained as the publishers.
The British Pharmacopoeia (BP) is the national pharmacopoeia of the United Kingdom.It is an annually published collection of quality standards for medicinal substances in the UK, which is used by individuals and organisations involved in pharmaceutical research, development, manufacture and testing.
An important step has also been taken in this direction by the publication under the authority of the Council of the Pharmaceutical Society of Great Britain of the British Pharmaceutical Codex (BPC), in which the characters of and tests for the purity of many unofficial drugs and preparations are given as well as the character of many glandular ...
Martindale Pharma – Martindale Pharmaceuticals - Ltd (Now Ethypharm UK) Mölnlycke – Mölnlycke Health Care Ltd; Mayne – Mayne Pharma plc; McNeil – McNeil Laboratories Ltd; Meda – Meda Pharmaceuticals Ltd; Medac – Medac (UK), Scion House, University of Stirling; MediSense – MediSense, Abbott Laboratories Ltd; Menarini – A ...
The Commission on Human Medicines (CHM) is a committee of the UK's Medicines and Healthcare products Regulatory Agency.It was formed in October 2005, and assumed the responsibilities of the Medicines Commission and the Committee on Safety of Medicines.
A British Approved Name (BAN) is the official, non-proprietary, or generic name given to a pharmaceutical substance, as defined in the British Pharmacopoeia (BP). [1] The BAN is also the official name used in some countries around the world, because starting in 1953, proposed new names were evaluated by a panel of experts from WHO in conjunction with the BP commission to ensure naming ...
[1] [2] In 2007 exports of pharmaceutical products from the UK totalled £14.6 billion, creating a trade surplus in pharmaceutical products of £4.3 billion. [3] UK Pharmaceutical employment of 73,000 in 2017 [4] compares to 114,000 as of 2015 in Germany, [5] 92,000 as of 2014 in France [6] and 723,000 in the European Union as a whole. [6]
The MHRA and the US Food and Drug Administration were criticised in the 2012 book Bad Pharma, [43] and in 2004 by David Healy in evidence to the House of Commons Health Committee, [44] for having undergone regulatory capture, i.e. advancing the interests of the drug companies rather than the interests of the public.